US 12,252,723 B2
Ketoreductase polypeptides and polynucleotides
Jeffrey C. Moore, Westfield, NJ (US); Jack Liang, South San Francisco, CA (US); Jonathan Penfield, Truckee, CA (US); Jovana Nazor, Milpitas, CA (US); Nikki Dellas, San Carlos, CA (US); Vesna Mitchell, Santa Clara, CA (US); Da Duan, Newark, CA (US); Iman Farasat, Rahway, NJ (US); Agustina Rodriguez-Granillo, Rahway, NJ (US); Grant Murphy, Rahway, NJ (US); and Nicholas Marshall, Rahway, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Jul. 14, 2023, as Appl. No. 18/352,899.
Application 17/239,953 is a division of application No. 16/605,576, granted, now 11,021,729, issued on Jun. 1, 2021, previously published as PCT/US2018/027450, filed on Apr. 13, 2018.
Application 18/352,899 is a continuation of application No. 17/239,953, filed on Apr. 26, 2021, granted, now 11,746,369.
Claims priority of provisional application 62/491,161, filed on Apr. 27, 2017.
Prior Publication US 2024/0068005 A1, Feb. 29, 2024
Int. Cl. C12P 41/00 (2006.01); C12N 9/02 (2006.01); C12N 9/04 (2006.01); C12N 15/70 (2006.01)
CPC C12P 41/002 (2013.01) [C12N 9/0004 (2013.01); C12N 9/0006 (2013.01); C12N 15/70 (2013.01); C12Y 101/01002 (2013.01); C12Y 120/01001 (2013.01)] 6 Claims
 
1. An engineered phosphite dehydrogenase variant having at least 90% sequence identity to the polypeptide sequence SEQ ID NO: 172 wherein said engineered phosphite dehydrogenase variant comprises an alanine at position 44 as compared to SEQ ID NO: 172.